Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M N Lub-de Hooge

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Annals of the Rheumatic Diseases|November 27, 2004
Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosusM N Lub-de Hooge, E G E de Vries, S de Jong, et al.
Clinical Pharmacokinetics|March 31, 2023
Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A ReviewT Y J Appeldoorn, T H Oude Munnink, L M Morsink, et al.
PDA Journal of Pharmaceutical Science and Technology|April 20, 2011
Intravenous administration of recombinant human IL-10 suppresses the development of anti-thy 1-induced glomerulosclerosis in ratsH Rachmawati, L Beljaars, C Reker-Smit, et al.
Clinical Pharmacokinetics|March 20, 2023
The Pharmacokinetics and Target Attainment of Antimicrobial Drugs Throughout Pregnancy: Part III Non-penicillin and Non-cephalosporin DrugsF Groen, J R Prins, M N Lub-de Hooge, et al.
Clinical Pharmacokinetics|January 20, 2023
Pharmacokinetics and Target Attainment of Antimicrobial Drugs Throughout Pregnancy: Part I-PenicillinsM R Hesse, J R Prins, M N Lub-de Hooge, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|December 20, 2005
Molecular imaging: what can be used todayP L Jager, M A de Korte, M N Lub-de Hooge, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 31, 2018
<sup>89</sup>Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work upFrederike Bensch, A H Brouwers, M N Lub-de Hooge, et al.
Pharmacology & Therapeutics|December 3, 2014
Targeting breast cancer through its microenvironment: current status of preclinical and clinical research in finding relevant targetsH H Nienhuis, S B M Gaykema, H Timmer-Bosscha, et al.
Breast (Edinburgh, Scotland)|November 17, 2009
Molecular imaging of breast cancerT H Oude Munnink, W B Nagengast, A H Brouwers, et al.
British Journal of Pharmacology|October 22, 2011
Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studiesE W Duiker, E C F Dijkers, H Lambers Heerspink, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Annals of the Rheumatic Diseases|November 27, 2004
Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosusM N Lub-de Hooge, E G E de Vries, S de Jong, et al.
Clinical Pharmacokinetics|March 31, 2023
Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A ReviewT Y J Appeldoorn, T H Oude Munnink, L M Morsink, et al.
PDA Journal of Pharmaceutical Science and Technology|April 20, 2011
Intravenous administration of recombinant human IL-10 suppresses the development of anti-thy 1-induced glomerulosclerosis in ratsH Rachmawati, L Beljaars, C Reker-Smit, et al.
Clinical Pharmacokinetics|March 20, 2023
The Pharmacokinetics and Target Attainment of Antimicrobial Drugs Throughout Pregnancy: Part III Non-penicillin and Non-cephalosporin DrugsF Groen, J R Prins, M N Lub-de Hooge, et al.
Clinical Pharmacokinetics|January 20, 2023
Pharmacokinetics and Target Attainment of Antimicrobial Drugs Throughout Pregnancy: Part I-PenicillinsM R Hesse, J R Prins, M N Lub-de Hooge, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|December 20, 2005
Molecular imaging: what can be used todayP L Jager, M A de Korte, M N Lub-de Hooge, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 31, 2018
<sup>89</sup>Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work upFrederike Bensch, A H Brouwers, M N Lub-de Hooge, et al.
Pharmacology & Therapeutics|December 3, 2014
Targeting breast cancer through its microenvironment: current status of preclinical and clinical research in finding relevant targetsH H Nienhuis, S B M Gaykema, H Timmer-Bosscha, et al.
Breast (Edinburgh, Scotland)|November 17, 2009
Molecular imaging of breast cancerT H Oude Munnink, W B Nagengast, A H Brouwers, et al.
British Journal of Pharmacology|October 22, 2011
Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studiesE W Duiker, E C F Dijkers, H Lambers Heerspink, et al.
Pageof 2